Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C154287
http://purl.obolibrary.org/obo/NCIT_C154287
|
|---|---|
| Preferred Name | Sotorasib |
| Definitions |
An orally available inhibitor of the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets, binds to and inhibits the activity of the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally available inhibitor of the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets, binds to and inhibits the activity of the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation. |
|---|---|
| label | Sotorasib
|
| prefLabel | Sotorasib
|
| in_subset |
See more
See less
|
| Preferred_Name | Sotorasib
|
| Is_Value_For_GDC_Property | |
| Display_Name | Sotorasib
|
| Maps_To |
KRAS Mutant-targeting AMG 510
Sotorasib
|
| PDQ_Open_Trial_Search_ID | 794411
|
| Has_Target | |
| FDA_UNII_Code | 2B2VM6UC8G
|
| prefixIRI | NCIT:C154287
|
| Accepted_Therapeutic_Use_For | adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)
|
| NCI_Drug_Dictionary_ID | 794411
|
| Contributing_Source |
CTRP
FDA
|
| subClassOf | |
| code | C154287
|
| type | |
| PDQ_Closed_Trial_Search_ID | 794411
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| CAS_Registry | 2296729-00-3
|
| NCI_META_CUI | CL555284
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |